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Abstract
Cardiovascular diseases are the leading cause of death in Poland. The most common cardiovascular risk factors are 
dyslipidemia and hypertension. Unfortunately, the percentage of patients with well-controlled dyslipidemia and hyper-
tension remains very low. This is mainly due to insufficient statin therapy. Perindopril and atorvastatin are substances 
with a documented efficacy in reducing the incidence of cardiovascular events. The use of these drugs in one capsule 
can cause a significant increase in the percentage of patients properly treated and reaching the target values of blood 
pressure and LDL-cholesterol.
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Introduction
Cardiovascular diseases remain the leading cause of 
death in Europe [1, 2]. In the Polish population, according 
to the results of the NATPOL study [3], dyslipidemia and 
hypertension are the two most common cardiovascular 
risk factors. Dyslipidemia occurs in 18 million Poles, and 
10.5 million adult Poles suffer from hypertension. About 
6.5 million Poles have hypertension and dyslipidemia [3] 
(Figure 1). A steady increase in the number of patients with 
hypertension and dyslipidemia is forecast [4].
In the observational POSTER study, conducted among 
42,338 patients who were under outpatient medical care 
with hypertension, 77.8% of patients had lipid profile dis-
orders and 68.3% had abdominal obesity. Over 25% of 
respondents smoked tobacco [5].
It is estimated that dyslipidemia also occurs in half of 
the hypertensive patients in the general population, which 
Figure 1. Prevalence of cardiovascular risk factors according to 
data from the NATPOL 2011 study (based on [3])
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Which patients have common indications 
for the use of an angiotensin-converting  
enzyme inhibitor and a statin?
Angiotensin-converting enzymes (ACE) and statins have 
been widely used in many patients for many years. In light 
of current guidelines, the combined use of an ACE inhibitor 
and a statin is recommended for patients:
 — with hypertension and dyslipidemia;
 — hypertension with high and very high cardiovascular risk;
 — hypertension and diabetes;
 — stable coronary artery disease with hypertension;
 — acute coronary syndrome — treated both conservatively 
and invasively.
The results of numerous studies on the use of statins 
in primary and secondary prevention, in which a significant 
percentage of the studied population were hypertensive 
patients, indicate that the optimal reduction in the glo-
bal risk of cardiovascular complications is obtained by 
the simultaneous reduction of blood pressure and low-
-density lipoprotein (LDL) cholesterol [8]. According to the 
Pol-SCORE scale, every man with hypertension aged over 
55 and every woman over 65 is at high or very high risk 
of cardiovascular death, so they should take a statin even 
though they have a normal lipid profile. The administration 
of an ACE inhibitor should be considered for patients with 
chronic coronary syndrome, especially with concomitant 
hypertension, left ventricular ejection fraction below 40%, 
diabetes or chronic kidney disease. Patients with documen-
ted coronary artery disease are at high risk and should be 
treated with statins [10].
is why the term ‘lipitension’ has recently become estab-
lished in the literature, suggesting firstly the coexistence 
of these diseases, and secondly their synergistic adverse 
effect on patient prognosis [6].
Why is the simultaneous control  
of hypertension and hypercholesterolemia 
so important?
The coexistence of hypertension and dyslipidemia potentiates 
cardiovascular risk. In both the joint guidelines of the Euro-
pean Society of Cardiology (ESC) and the European Society 
of Hypertension (ESH) published in 2018, and in the 2019 
guidelines of the Polish Society of Hypertension (PTNT, Pol-
skie Towarzystwo Nadciśnienia Tętniczego), risk assessment 
is recommended of the cardiovascular system in patients 
with hypertension [7, 8]. According to the assessment of 
global cardiovascular risk based on the Framingham model 
in a patient with hypertension, the presence of dyslipidemia 
as a single cardiovascular risk factor qualifies the patient as 
being at least at moderate global risk (Table 1). Hyperten-
sion and dyslipidemia are well recognised as risk factors for 
vascular diseases, which is why patients with these factors 
are often burdened with very high global risk [8].
Proper control of hypertension and dyslipidemia is 
important because of the possibility of reducing the risk 
of death and the incidence of cardiovascular disease. It 
is estimated that in Poland the percentage of premature 
mortality, i.e. deaths of people aged 25–64 due to cardio-
vascular diseases, is more than two times higher than in 
other European Union countries [9].
Table 1. Assessment of global risk in a patient with hypertension modelled on the Framingham model (based on [8])
BP [mm Hg]













SBP ≥ 180 
DBP ≥ 110
Stage 1 No risk factors Low Low Moderate High
1–2 risk factors Low Moderate Moderate/ 
/high
High





Stage 2 Organ complications, 
diabetes without compli-
cations, grade 3 CKD
Moderate/ 
/high
High High Very high
Stage 3 Overt cardiovascular 
disease, complicated 
diabetes, CKD ≥ grade 4
Very high Very high Very high Very high
BP — blood pressure; SBP — systolic blood pressure; DBP — diastolic blood pressure; CKD — chronic kidney disease
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In which patient groups are ACE inhibitors 
preferred over sartans?
According to the PTNT guidelines of 2019, ACE inhibitors are 
antihypertensive drugs of the first choice in patients with:
 — heart failure;
 — chronic coronary syndrome;
 — atherosclerosis of the lower extremities;
 — metabolic syndrome;
 — diabetes;
 — hyperuricemia/gout;
 — potency disorders;
 — chronic kidney disease;
 — albuminuria;
 — renal failure [8].
ACE inhibitors are not drugs with the same properties; 
they differ within the group. That is why the authors of the 
PTNT guidelines from 2019 distinguished between some 
of them in specific indications. Perindopril, ramipril or 
zofenopril are preferred in patients with hypertension and 
chronic coronary syndrome.Perindopril and ramipril are 
preferred in patients with hypertension and diabetes or 
cardiovascular or metabolic complications [8].
In addition, in the recommended combination regimen 
for combined antihypertensive therapy, depending on the 
presence of comorbidities, ACE inhibitors are present in 
each recommended combination:
 — ACE inhibitor and beta-blocker — in patients who have 
had a heart attack or heart failure;
 — ACE inhibitor/sartan and thiazide/thiazide diuretic — in 
patients with diabetes, after a stroke, with renal dys-
function, in the elderly;
 — ACE inhibitor/sartan and calcium antagonist — in pa-
tients with diabetes or with metabolic syndrome [8].
The strong position of ACE inhibitors in subsequent 
guidance documents has been strengthened thanks to 
the results of studies and meta-analyses confirming the 
hypotensive efficacy of the ACE inhibitor, but above all the 
reduction in the incidence of hard endpoints.
Van Vark et al. [11] analysed 158,998 patients from 
20 clinical trials who had been randomised to treatment 
with a drug blocking the renin–angiotensin–aldostero-
ne system (N = 71,401) or to a no-treatment control 
group (N = 87,597). Seven clinical studies concerned 
ACE inhibitors and 13 concerned sartans. There were 
significant differences in the subanalysis of the effect 
of ACE inhibitors and sartans on the reduction of overall 
and cardiovascular mortality. The use of ACE inhibitors 
was associated with a statistically significant (p = 0.004) 
reduction in the death rate by 10% and cardiovascular 
death by 12% (p = 0.051), while the use of sartans did 
not significantly affect total mortality [hazard ratio (HR) 
0.99, p = 0.683] or cardiovascular mortality (HR 0.96, 
p = 0.143). The difference in the effect of both drug 
groups on total mortality in favour of ACE inhibitors was 
statistically significant (p = 0.036).
Similar conclusions are included in the next meta-ana-
lysis, by Savarese et al. [12], based on the analysis of data 
of 108,212 patients at high cardiovascular risk (excluding 
patients with heart failure) treated with ACE inhibitors or 
sartans. On the other hand, in a Korean registry including 
12,481 patients after myocardial infarction, Choi et al. 
[13] showed a reduction in cardiovascular and general 
mortality in a one-year follow-up in patients treated with 
ACE inhibitors compared to patients treated with sartans.
Brugts et al. [14] evaluated the incidence of end events 
in hypertensive patients treated with ACE inhibitors or 
sartans. Their meta-analysis of 18 studies showed that 
patients treated with ACE inhibitors were less likely to have 
fatalities due to general and cardiovascular causes, as well 
as heart attacks.
What is the synergistic effect  
of atorvastatin and perindopril  
on cardiovascular protection?
Perindopril is an ACE inhibitor with high antihypertensive 
effectiveness and many beneficial properties that result 
from its pleiotropic effect. It has been shown to be effective 
in the prevention of premature death and cardiovascular 
complications in many clinical studies: ASCOT (Anglo-
-Scandinavian Cardiac OuTcomes), ADVANCE (Action in 
Diabetes and VAscular Disease: Preterax and DiamicroN 
MR Controlled Evaluation), and HYVET (Hypertension in the 
Very Elderly Trial) [15–17].
Perindopril has a higher binding specificity to the tis-
sue ACE fraction (‘tissue’ ACE inhibitor) than traditional 
hydrophilic ACE inhibitors, such as enalapril and captopril, 
which bind strongly to the enzyme plasma fraction (‘plasma’ 
ACE inhibitors). There are no clinically significant differ-
ences between the two groups (i.e. ‘plasma’ vs. ‘tissue’) 
of ACE inhibitors in reducing cardiovascular morbidity and 
mortality, but drugs from the ‘tissue’ ACE inhibitor group 
are characterised by more favourable pharmacokinetic 
properties, mainly in terms of the length of the effective 
hypotensive period, i.e. the T/P (through-to-peak ratio) ratio, 
as well as a greater ability to selectively bind bradykinin 
in ACE compared to ‘plasma’ ACE inhibitors, and this may 
be of clinical significance [18]. Ceconi et al. [18] showed 
that among many active metabolites of ACE inhibitors, of 
which enalaprilat, perindoprilat, quinaprilat, ramiprilat and 
trandolaprilat were studied, perindoprilat showed the great-
est ability to selectively bind bradykinin. This specificity is 
measured by the selective bradykinin/angiotensin I binding 
index, which is 1.44 for perindopril, and for other tissue 
ACE inhibitors it also exceeds 1.0 (ramipril — 1.16 and tran-
dolapril — 1.08, respectively), while the lowest 1.0 plasma 
(balance of binding to bradykinin and angiotensin I) for the 
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of hypertension, and statins in this group of patients 
significantly improve prognosis. Taking into account the 
LDL-cholesterol target values to be achieved in patients 
with hypertension and dyslipidemia, it is advisable to use 
high-dose statins such as atorvastatin or rosuvastatin in 
this group of patients.
The synergistic effect of perindopril and atorvastatin 
may be due to their antiatherosclerotic effect. Both drugs 
stabilise atherosclerotic plaque by inhibiting endothelial 
dysfunction, oxidation of LDL-cholesterol and smooth 
muscle proliferation.
In the lipid arm of the ASCOT study, 10,305 patients 
with total cholesterol below 250 mg/dL were randomised 
to receive either a placebo or atorvastatin. Compared to the 
placebo, atorvastatin reduced the number of non-fatal or 
fatal coronary heart attacks by 53% [HR 0.47, 95% confi-
dence interval (CI) 0.32–0.69, p < 0.0001] among patients 
assigned to therapy based on perindopril and amlodipine, 
while in the group of patients treated with atenolol and 
thiazide the reduction in the incidence of the endpoint was 
only 16% (HR 0.84; 95% CI 0.60–1.17, p = 0.30), which 
may result from the special synergy of atherosclerosis, 
atorvastatin, perindopril and amlodipine (Figure 2) [22]. In 
addition, based on a 16-year observation of patients from 
the ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes 
Trial — Lipid Lowering Arm) study, Gupta et al. [23] showed 
that adding statins to antihypertensive drugs compared to 
a placebo reduced cardiovascular mortality by 15%.
How to improve compliance  
for a patient being treated  
for hypertension and dyslipidemia?
According to data from the World Health Organisation 
(WHO), almost half of patients do not follow the treatment 
regimen recommended by their doctors. This phenomenon 
is particularly common among people with chronic, mild or 
asymptomatic diseases, requiring long-term treatment and 
the use of several medications. These conditions include 
hypertension and dyslipidemia.
In many patients, hypertension and lipid disorders are 
not treated efficiently. According to the NATPOL 2011 study, 
hypercholesterolemia in Poland is successfully treated in 
only 11% of patients, and hypertension in 26% [24]. While 
the effectiveness of hypertension treatment in Poland has 
been steadily increasing, from 12% to 26% according to the 
NATPOL study from 2002 and 2011, the effectiveness of 
dyslipidemia treatment remains very low. This is due to both 
the lack of patient cooperation in the use of lipid-lowering 
therapy, and the prescription of low doses of statins.
The results of the EUROASPIRE (European Action on 
Secondary Prevention through Intervention to Reduce 
Events) study, in which secondary prevention was assessed 
in people with coronary artery disease (after myocardial 
plasma ACE inhibitor is enalapril. Moreover, comparing the 
equivalent doses and binding capacity of angiotensin I, 
it has been shown that perindoprilat has an almost 50% 
greater bradykinin binding capacity than enalaprilate [18]. 
This biochemical property of perindopril may explain its 
beneficial effect in the prevention of cardiovascular events. 
The ACE is also responsible for the breakdown of brady-
kinin, whose concentration in the blood increases during 
treatment with ACE inhibitors. Increased bradykinin levels 
have potentially beneficial vasodilatatory, cardioprotective 
and anti-hypertrophic effects. The multicentre COMPLIOR 
study showed that long-term administration of perindopril 
increased the elasticity and compliance of the aorta [19]. 
An important pleiotropic effect of perindopril is a protective 
effect on endothelial function, as demonstrated by a group 
of researchers in the PERFECT study (PERindopril-Function 
of the Endothelium in Coronary artery disease Trial), which 
is a subanalysis of the EUROPA study [20]. This study 
evaluated the effect of long-term perindopril 8 mg/day on 
the rate of flow-mediated vasodilatation (FMD), an expo-
nent of endothelial function. In a group of 333 patients, 
a beneficial, although not statistically significant, effect of 
perindopril on improving endothelial function, measured 
as an increase in FMD after 36 months of therapy, was 
demonstrated. The properties of perindopril are given in 
Table 2 [21].
The effect of statins is both a lipid-lowering effect and 
an additional non-lipolipemic effect resulting from the 
pleiotropic effect of statins, which is a consequence of:
 — inhibition of fatty acid metabolism;
 — inhibiting the inflammatory reaction;
 — anticoagulant effect;
 — a beneficial effect on the synthesis of nitric oxide, which 
improves the function of vascular endothelium;
 — stabilisation of atherosclerotic plaque.
These mechanisms of pleiotropic action of statins 
are particularly important in patients with complications 
Table 2. Properties of perindopril compared to other angiotensin-
-converting enzyme inhibitors (based on [21])
Stronger inhibition of the angiotensin-converting enzyme  
in blood and target tissues
Greater selectivity in relation to target organs
Greater selectivity for bradykinin binding
Greater efficiency in inhibiting endothelial cell apoptosis
Greater increase in the content and activity of nitric oxide 
synthase in aortic endothelium and cardiomyocytes
Greater antioxidant, anti-inflammatory, anticoagulant  
and profibrinolytic effect
Improvement of the coronary reserve in chronic coronary 
syndrome
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infarction, percutaneous coronary intervention, and coro-
nary artery bypass grafting, revealed that over 80% patients 
had elevated cholesterol values. Despite the increase in the 
frequency of lipid-lowering therapy (up to 85%) in subse-
quent editions of the study, the effectiveness of achieving 
the target concentration of LDL-cholesterol was low and 
amounted to 30% [25].
In the POL-FOKUS study, it was shown that seven out 
of 10 patients with hypertension receive simultaneously 
antihypertensive drugs and a statin. Only four out of these 
seven achieved satisfactory control of LDL-cholesterol 
[26]. The low rate of statin use among Polish patients 
in almost every age group is also demonstrated by data 
from the National Health Fund (NFZ, Narodowy Fundusz 
Zdrowia). In the methodology of the study, medication 
possession ratio (MPR) was used in the assessment of 
adherence — an indicator estimated on the basis of is-
sued prescriptions and dispensed prescriptions. An MPR 
of 100% means that the number of tablets the patient 
has is equal to the number of days from the implemen-
tation of one prescription to the implementation of the 
next prescription (i.e. the patient bought a 90-tablet pack 
of statins, and bought another pack after 90 days). The 
lower the MPR rate, the less frequently the patient com-
pleted prescriptions and had fewer medications than the 
number of days between subsequent prescriptions. The 
study by Wiśniowska and Skowron [27] showed that the 
average MPR value was 55.8% (52–63% in different age 
group ranges). Compliance has not reached the minimum 
level guaranteeing clinical benefits (80%) in any age 
group. An appropriate level of compliance with medical 
recommendations regarding statin treatment was found 
in 27.2% of respondents. Most people in all age groups 
discontinued statin treatment during the first 30 days 
of treatment [27].
In order to improve the quality of dyslipidemia treat-
ment, it is necessary to simplify therapy, especially in 
patients with concomitant hypertension. It has been shown 
that the highest probability of continuing therapy was asso-
ciated with the inclusion of several drugs at the same time 
or in a short period of time. It was observed that patients 
starting antihypertensive and lipid-lowering therapy on 
the same day, or at most within one month, adhered more 
closely to medical recommendations by 34% [28], while 
patients in whom lipid-lowering and antihypertensive drugs 
were introduced across a greater interval of time were less 
likely to follow the therapeutic regimen [29].
Chapman et al. [28], in an American patient popula-
tion, showed that the adherence of patients treated for 
hypertension and dyslipidemia significantly deteriorated 
after the first six months of therapy and was only 35.8%. 
The authors of this report emphasised that reducing the 
number of tablets taken by the patient when starting 
therapy for hypertension and dyslipidemia may improve 
patient adherence.
One of the most effective methods to increase the 
effectiveness of antihypertensive and lipid-lowering treat-
ment is to reduce the number of tablets ingested. A sim-
plification of the treatment regimen, in numerous studies 
and meta-analyses, has been associated with a significant 
improvement in compliance with medical recommenda-
tions, regardless of the group of drugs used. Significant 
differences have been observed between patients using 
drugs once daily compared to their use more often. It has 
also been observed that fewer doses of medication taken 
by patients during the day were associated not only with 
improved collaboration, but also with increased treatment 
efficacy.
To sum up, using atorvastatin/perindopril in one cap-
sule can result in greater treatment effectiveness and 
Figure 2A, B. The incidence of non-fatal myocardial infarction or death due to coronary artery disease in the ASCOT-LLA (Anglo-Scandinavian 
Cardiac Outcomes Trial — Lipid Lowering Arm) study (based on [22]); NS — not statistically significant
A B
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easier therapeutic goal achievement, both in terms of 
lowering blood pressure and affecting the result of the lipi-
dogram. Good blood pressure control may be an indicator 
that the patient is not taking only a hypotensive drug, but 
also an additional statin, in one capsule.
Can atorvastatin be given in the morning?
It is generally accepted that lipid-lowering drugs should 
be used in the evening, due to the peak of endogenous 
cholesterol synthesis in the liver at night. This rule applies 
to older generation statins, i.e. pravastatin, lovastatin and 
simvastatin, which have a short half-life (approx. 6 h). Con-
versely, atorvastatin and rosuvastatin, the most commonly 
used statins, have longer half-lives and can also be used 
in the morning. In addition, atorvastatin metabolites also 
inhibit cholesterol production.
Awad et al. [30] compared the results of lipidograms 
in patients treated with statins administered in the mor-
ning and in the evening in a meta-analysis involving 
1,034 patients. In patients treated with long-acting statins, 
no differences in lipidogram parameters were observed 
between the groups of patients receiving morning and 
evening statins.
The recommendation of using a statin in the morning 
significantly increases the proportion of patients who re-
gularly take medicines.
Perindopril with atorvastatin  
in one capsule — will this drug  
be used in my daily practice?
1. This drug is a combination of effective 
substances with proven action  
in the prevention of cardiovascular events
Perindopril is a potent long-acting hypotensive agent, and 
atorvastatin is a potent statin. Both drugs are characterised 
by unique properties and pleiotropic effects. The synergy of 
their antiatherosclerotic activity has been demonstrated in 
relation to the reduction in endpoint frequency in numerous 
studies (e.g. EUROPA, ASCOT-LLA).
2. A fixed combination drug helps  
to improve compliance  
with medical recommendations
In Poland, hypertension and especially dyslipidemia are 
under-treated. Only 11% of patients reach their LDL-cho-
lesterol target. The lack of control of these two risk factors 
eliminates the clinical benefits of taking medication. The 
recommendation of combination therapy consisting of 
perindopril and atorvastatin may significantly increase the 
proportion of patients taking a statin regularly.
3. The fixed combination drug of atorvastatin 
and perindopril has indications in numerous 
groups of patients, and the wide dose range 
allows selection of therapy in many patients
The fixed combination drug consisting of perindopril and 
atorvastatin can be used in patients with hypertension and 
dyslipidemia, chronic coronary syndrome, but also after 
acute coronary syndromes and coronary revascularisation. 
The wide range of six practical doses allows for individua-
lised treatment of both hypertension and dyslipidemia in 
most patients (Table 3) [31].
It is worth remembering that if a greater reduction of 
blood pressure is needed, the combination drug atorva-
statin/perindopril/amlodipine is available on the Polish 
market, which makes it possible to continue the treatment 
with the fixed combination drug.
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Table 3. Available doses of the fixed combination drug of atorva-
statin/perindopril (based on [31])
Atorvastatin Perindopril
10 mg 5 mg 10 mg
20 mg 5 mg 10 mg
40 mg 5 mg 10 mg
Streszczenie
Choroby układu sercowo-naczyniowego są główną przyczyną zgonów w Polsce, a najczęściej występujące czynniki ryzyka 
sercowo-naczyniowego to dyslipidemia i nadciśnienie tętnicze. Niestety odsetek chorych z dobrze kontrolowanymi dys-
lipidemią i nadciśnieniem tętniczym pozostaje bardzo niski. Wynika to głównie z niedostatecznej terapii statynami. Per-
indopril i atorwastatyna to substancje o udokumentowanym wpływie na ograniczenie częstości występowania zdarzeń 
sercowo-naczyniowych. Zastosowanie tych leków w jednej kapsułce może spowodować istotny wzrost odsetka chorych 
właściwie leczonych i osiągających docelowe wartości ciśnienia tętniczego i cholesterolu frakcji LDL.
Słowa kluczowe: nadciśnienie tętnicze, hipercholesterolemia, perindopril, atorwastatyna, leczenie skojarzone
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